Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 16/20 | 0.57 |
| ▸ | S1PR5 | Q9H228 | 11/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 9/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.46 |
| ▸ | TPH1 | P17752 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4741310 | 0.88 | S1PR1 (0.54) | S1PR1S1PR5S1PR4S1PR3 | |
| SCHEMBL4741601 | 0.87 | S1PR1 (0.52) | S1PR1S1PR5S1PR4S1PR3TPH1 | |
| SCHEMBL451098 | 0.83 | S1PR1 (0.56) | S1PR1S1PR5S1PR4S1PR3TPH1 | |
| SCHEMBL3456664 | 0.83 | S1PR1 (0.56) | S1PR1S1PR5S1PR4S1PR3TPH1 | |
| SCHEMBL3456844 | 0.81 | S1PR1 (0.52) | S1PR1S1PR5S1PR4S1PR3TPH1 | |
| SCHEMBL16591182 | 0.80 | S1PR1 (0.56) | S1PR1S1PR5S1PR4S1PR3TPH1 | |
| SCHEMBL30223647 | 0.80 | S1PR1 (0.56) | S1PR1S1PR5S1PR4S1PR3TPH1 | |
| SCHEMBL3456144 | 0.79 | S1PR1 (0.52) | S1PR1S1PR5S1PR4S1PR3TPH1 | |
| SCHEMBL13269548 | 0.76 | NPC1 (0.46) | S1PR1S1PR5S1PR4S1PR3 | |
| SCHEMBL28776656 | 0.75 | S1PR1 (0.54) | S1PR1S1PR5S1PR4S1PR3TPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1549640-A4 | 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)AZETIDINE-3-CARBOXYLATES AND 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)PYRROLIDINE-3-CARBOXYLATES AS EDG RECEPTOR AGONISTS | MERCK & CO INC (US) | 2008-08-06 | — | — | EP | disclosed |
| US-7199142-B2 | 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists | MERCK & CO., INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-20050245575-A1 | 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists | MERCK & CO., INC. | 2005-11-03 | — | — | US | disclosed |
| EP-1549640-A2 | 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)AZETIDINE-3-CARBOXYLATES AND 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)PYRROLIDINE-3-CARBOXYLATES AS EDG RECEPTOR AGONISTS | Merck & Co., Inc. (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2003105771-A2 | 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)AZETIDINE-3-CARBOXYLATES AND 1-((5-ARYL-1,2,4-OXADIAZOL-3-YL)BENZYL)PYRROLIDINE-3-CARBOXYLATES AS EDG RECEPTOR AGONISTS | MERCK & CO., INC. (US) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245575-A1 | 1-((5-aryl-1,2,4-oxadiazol-3-yl) benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl) pyrrolidine-3-carboxylates as edg receptor agonists | EDNRA, OXGR1, EDNRB | S1PR1 217/4885S1PR5 281/4885S1PR4 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.